Highlights

• This is the first study to suggest that postload glucose spikes (PGS), defined as the difference between 2-hour postload and fasting glucose measured after myocardial infarction (MI), are robust enough to predict post-MI prognosis in patients without known or newly diagnosed diabetes.
• In patients without diabetes, PGS is a stronger determinant of post-MI prognosis than 2-hour postload glucose.

Highlights

1. Three novel heterozygous missense mutations were identified in a patient with the triad of diabetic ketoacidosis, hypertriglyceridemia, and acute pancreatitis.
2. Plasmapheresis is effective and safe in reducing triglycerides levels.

Highlights

• Higher ECW/TBW ratio is independently associated with poorer cognitive function.
• Higher pulse pressure partially mediates the association.
• The association is observed in domains of delayed memory, language, and attention.

Highlights

• Smoking cessation, treating low-density lipoprotein cholesterol to target levels, preventing diabetes, and highly individualized glucose control are crucial for minimizing the risk of subsequent in-hospital death and complications after coronary artery bypass grafting (CABG).
• Among patients with diabetes, strict glucose control significantly increased the risk of in-hospital mortality compared with moderate glucose control, whereas among nondiabetic patients with stress hyperglycemia, it reduced the risk of major complications. Thus, optimal glycemic control targets after CABG may differ among patients with and without previous diabetes.

Highlights

• The progression and outcome of coronavirus disease 2019 (COVID-19) may relate to diabetes; however, whether the diabetic treatment principles can be used for COVID-19 is unclear.
• Here, we screened all commonly used clinical oral hypoglycemic drugs to identify the potential inhibitors of M^pro and found six candidate drugs, including repaglinide, canagliflozin, glipizide, gliquidone, glimepiride, and linagliptin.
• The results indicated that these six antidiabetic drugs may have an extra effect on the treatment of COVID-19, although further preclinical experiment and clinical research are necessary to confirm these findings.

Highlights

• Hyperglycemia has been reported in almost half of the patients infected with coronavirus disease 2019.
• In critically ill patients, hyperglycemia is associated with increased morbidity and mortality, irrespective of preexisting diabetes.
• In our study, patients with blood glucose ≥140 mg/dL and admitted to the intensive care unit were found to have the worst outcomes in terms of mortality, mechanical ventilation need, and intensive care unit length of stay.
• Further studies are needed to clarify if outcomes significantly improve with tighter glucose targets.

Highlights

• The level of urinary α₁-microglobulin to creatinine ratio (A1MCR) increases with longer diabetes duration.
• Patients with a diabetes duration >14 years have a higher tubular damage rate.
• Being male and a diabetes duration >14 years have an interaction effect on increased A1MCR.

Highlights

• Sodium glucose cotransporter 2 (SGLT2) inhibitors have favorable pleiotropic effects in patients with diabetes mellitus and cardiovascular or renal disease.
• The benefits of SGLT2 inhibitors may extend to portal hypertension, but they have not been formally evaluated in patients with cirrhosis.
• Our study is the first to provide clinical data for SGLT2 inhibitors in a cohort of patients with cirrhosis, and our findings support ongoing evaluation in the form of a clinical trial.

Highlights

• Our multicenter study reports a higher proportion of diabetic ketoacidosis presentation of over 60% in newly diagnosed patients with type 1 diabetes with or without confirmed coronavirus disease 2019 (COVID-19) at diagnosis.
• This finding is suggestive of delays in seeking care during the COVID-19 pandemic.